La presente tesis consiste en un plan para el desarrollo de la producción y comercialización de ácido gálico obtenido del polvo de la Tara. El ácido gálico se utiliza principalmente en la industria farmacéutica como insumo de productos para la salud y es un producto que se obtiene de la extracción de los taninos que se encuentran en el polvo de la tara. De acuerdo con la consultora Wise Guy Reports, en el mercado internacional se ha estimado el consumo de ácido gálico a nivel mundial en 2019 en US$ 58 millones de dólares, con un potencial de crecimiento hacia el año 2024 de US$ 90 millones de dólares. La producción de Tara se da en diversas regiones del país, lo que facilita el acceso a la materia prima directamente del productor a las empresas que producen el polvo de Tara, y permite la disponibilidad del principal insumo del ácido gálico a precios competitivos. Se tomó conocimiento de tres procesos para obtener ácido gálico por lixiviación y se seleccionó el proceso de extracción utilizando como solvente al etanol, debido a que es el proceso que provee una mejor calidad y pureza acorde con los objetivos de calidad previstos. Teniendo en consideración el acceso y disponibilidad de la materia prima, así como el proceso productivo seleccionado, se realizó el estudio de la producción estimada y comercialización requerida, teniendo en consideración una participación de mercado previamente establecida, para ello se ha previsto implementar una pequeña planta productiva, contar con una estructura organizacional de soporte para la producción y comercialización, y desarrollar un proceso de difusión y comercialización. El mayor consumo se da en los mercados de Norte América, Europa, China y Sudamérica. Si bien la industria farmacéutica es el principal consumidor de ácido gálico y hay una producción nacional, no se observa un consumo local significativo de ácido gálico debido a la tendencia hacia la importación de medicamentos, en consecuencia, hemos considerado el destino de la producción a los mercados extranjeros que tiene un mayor consumo e incremento de la demanda. Finalmente, realizamos la evaluación de la viabilidad financiera del plan considerando un periodo de crecimiento de 10 años y satisfaciendo los objetivos de participación de mercado y rentabilidad deseada. / Gallic acid is extracted from Tara powder. Tara is a fruit cultivated throughout Peru. Gallic acid is mainly used in the health area where its application has contributed in studies to achieve a progress on treatments of several diseases. According to Wise Guy Reports consultant, the worldwide consumption of gallic acid during 2019 was estimated in 58 million dollars with a potential growth of 90 million dollars towards 2024. The highest consumption occurs in North America, Europe, China and South America markets. The biggest gallic acid producer is china where find the top 10 producers, such as Jiurui Biology, Bei Yuan Chemical and, Hunan Linong. Peru is the world’s main producer of Tara, from which Tara powder is extracted, input used to obtain gallic acid. The production of Tara is performed on different regions of the country, which allows access to the raw material directly from the producer to the companies that produce an export Tara powder, making possible to access to competitive prices. The pharmaceutical industry is the main consumer of gallic acid. Although, there is a national production of medicines, there is also a strong trend towards imports. Consequently, gallic acid producers direct their production to foreign markets that show a greater consumption and an increased demand and from where medicines are imported. / Trabajo de investigación

Supercritical fluid chromatography (SFC) is an expanding chromatographic technique that is part of the evolving field of green chemistry due to its short run times and use of non-toxic solvents in combination with recycled CO2. The use of a suitable column is essential for separation science in general and there is a wide variety of SFC compatible columns available on the market. In collaboration with the AstraZeneca Gothenburg Separation Science Laboratory (SSL), an investigation of 25 stationary phases in combination with four different mobile phases was conducted in order to evaluate interactions between the mobile phase, stationary phase and analytes. The aim was to find a new column set, able to operate with a wide range of molecules at both analytical and preparative scale. The 36 compounds analysed were chosen to represent the chemical space suitable for current and foreseen compounds of interest within AstraZeneca. Furthermore, to mitigate the risk of degradation of sensitive compounds in basic conditions, different combinations of basic stationary phases and neutral mobile phases were investigated.The study was performed using a Waters Acquity UPC2 system equipped with a photodiode array (PDA) detector and a single quadrupole detector (SQD). The data was gathered by Empower 3 and analysed using statistical methods to evaluate corelations and orthogonality with the help of Python. Visualisations were produced using Pandas, XLstat and SIMCA.The results evaluated retention time, symmetry factor, distribution of retention times of compounds over the columns, and DMSO retention. The results showed that MeOH and the basic additive NH3 included in the mobile phase composition provided the shortest retention times, best peak symmetry and distribution of compounds. It was concluded that Kromasil 2EP, Kromasil Diol, DC Pak PBT, and Kromasil NH2 columns represent a diverse set for the intended chemical space. They all also operate with good results without additive, for the compounds used. / Superkritisk vätskekromatografi (SFC) är en växande kromatografisk teknik som tack vare sina snabba analyser, användandet av icke toxiska lösningsmedel, samt återvinningsbar CO2 utgör en del av den allt mer populära “gröna” kemin. Det finns en mängd kolonner utvecklade för SFC på marknaden, och att använda rätt sorts stationär fas är en viktig del för separationen av olika ämnen. I samarbete med Separation Science Laboratory på AstraZeneca i Göteborg, har 25 olika stationära faser i kombination med fyra mobila faser studerats för att analysera interaktionerna mellan faserna och analyterna. Målet är att hitta en uppsättning av kolonner som kan användas vid upprening av substanser med en stor variation av kemiska egenskaper/deskriptorer. För den här studien har 36 molekyler som representerar den kemiska rymd som AstraZeneca jobbar i använts. För att minimera risken av nedbrytning av känsliga molekyler i basiska miljöer, är även basiska kolonner med neutrala mobilfaser inkluderade. Under studien användes SFC systemet Acquity UPC2, utrustad med en Diode array detektor, en Single quadrapole detektor samt Empower 3 för insamling av data. Den statistiska analysen utfördes i Python och visualiseringen gjordes med hjälp av Pandas, Xlstat och Simca.Resultaten utvärderades med avseende på retentionstid, symmetrifaktorn, fördelningen av substanser över kolonnerna och retention av DMSO. Resultaten visade att MeOH med NH3 som additiv i mobilfasen gav kortast retentionstid, bäst symmetri och bredast fördelning av substanser. Slutsatserna var att kolonnerna Kromasil 2EP, Kromasil Diol, DC Pak PBT, and Kromasil NH2 tillsammans representerar den diversa uppsättning av kolonner som passar den kemiska rymnd som användes i studien. Samtliga kolonner kan även köras med goda resultat i neutrala mobila faser, med de betingelser som använts.

Energy consumption is one of the major contributors to greenhouse gas emissions and to climate change. Renewable energy sources are one way of mitigating the problem, but behavioral change and reductions in consumption are also required. In addition, little is known about how energy conservation behaviors are driven or hindered at workplaces, but it has been found in previous research that employee engagement is an important factor. Therefore, this study takes a mixed method approach utilizing the framework of Community-Based Social Marketing at a pharmaceutical manufacturing site in Sweden to investigate drivers and barriers to energy conservation, designing an intervention aiming at increasing employee engagement as well as changing behaviors, and evaluating the study using interviews, surveys and real time measurements. The findings of this study suggest that several factors act as barriers and drivers to energy conservation behaviors at work, e.g., interest, organizational culture, work processes and commitment from the company and management. The designed intervention, an inclusionary trans- disciplinary workshop, seems to have increased engagement and has preliminarily influenced pro-environmental behavior changes, as well as mitigated some barriers and strengthened some drivers.

Adopting sustainability practices in both planned and current operations is increasingly important to many organizations. Due to increased awareness various companies are adopting life cycle thinking. For example, life cycle considerations from raw material extraction to final disposal of products or services are requested in environmental management system standard ISO 14001:2015. Octapharma is a biopharmaceutical company producing various medical products for the treatment of haematology, immunotherapy and critical care. The desire to incorporate environmental life cycle thinking into investment projects led to the research question of how this can be achieved at Octapharma in Stockholm. The objectives included a qualitative investigation of current environmental management strategies practiced in investment projects today. Secondly, a case study investment project was used to explore how one of the most commonly practiced life cycle management (LCM) tools, life cycle assessment (LCA), can be applied for the comparison of two alternative process technologies. The results showed that Octapharma today considers environmental aspects in some investment projects, such as construction, but it may be improved in other types of investment projects. Therefore, specific suggestions and modifications of the project model, in relation to life cycle management literature was developed for important checkpoints in the project management model. Lastly the case project comparative LCA showed that one of the technologies had a significant larger environmental footprint. / Inkludering av ett hållbarhetsperspektiv i företags nuvarande och framtida verksamhet har fått ökande betydelse. På grund av större medvetenhet inkluderar flera organisationer ett livscykeltänk, dvs. utvärdering av miljöpåverkan från råvaruextraktion till avfallshantering av både produkter och tjänster. Bland annat ISO 14001:2015, en miljöledningsstandard, har infört krav på livscykeltänk i certifierade verksamheter. Octapharma är ett läkemedelsföretag som tillverkar produkter inom hematologi, immunterapi och intensivvård. På grund av ett intresse för livscykeltänk i investeringsprojekt på Octapharmas Stockholmsfabrik skapades ett behov av att undersöka hur detta skulle kunna åstadkommas. Delmålen i detta projekt innefattar en kvalitativ undersökning om nuvarande inkludering av miljöaspekter i investeringsprojekt med viktiga projektintressenter i verksamheten. En kvantitativ jämförande livscykelanalys (LCA) av ett avslutat investeringsprojekt syftade till att genomföra en LCA av två olika processteknologier. Resultatet visar att Octapharma idag inkluderar miljöfrågor i vissa typer av projekt, framför allt byggprojekt, men implementeringen i andra projekt kan förbättras. Fortsättningsvis resulterade litteratursökningen och den kvalitativa undersökningen i ett antal förslag på förbättringar i projektmodellen på punkter där miljöfrågor är extra viktiga för slutresultatet. Den jämförande LCAn visade att den ena teknologin hade en betydligt större miljöpåverkan.

This study empirically examined the relationship between strategic orientation of an organization and the overseas activities it pursues. It is argued that the nature and extent of an organization’s overseas involvement will be a function of its dominant strategic orientation and the distinctive competences associated with such an orientation. Several hypotheses that build on the central notion of the "common thread", first articulated by Ansoff (1965), were developed and tested. Building on a systems typology of multinationals (Cheng & Ramaswamy, 1989), this study utilized many new measurement approaches that help measure level of internationalization in a multidimensional manner. Set in the drugs and pharmaceutical industry, the empirical effort used objective secondary data to characterize both dependent and independent constructs. Tests of the hypotheses indicated that distinct multinationality profiles were associated with different strategic orientations. Prospector organizations were found to emphasize their distinctive competences in research and development and marketing in their overseas efforts. They tended to operate a larger number of overseas R&D facilities and overseas sales offices than their Defender counterparts. Further, they also exhibited a marked tendency to spread these activities over a larger number of countries than Defender firms. These findings support the theoretical notion that every organization builds around its distinctive competences to achieve competitive advantage (Ansoff, 1965; Miles & Snow, 1978; Porter, 1980). It was hypothesized that Defender firms would exhibit higher levels of overseas production activity than Prospector firms in keeping with their competence in manufacturing and cost control. However, this hypothesis was not supported. Consistent with Horst (1972), further analysis revealed that the age of the firm may play a significant role in influencing internationalization of production activity. This study represents the first effort in applying a typology of strategy to examine multinational corporations. Further, the study provides evidence to show that: (a) Strategic orientation of a firm plays a central role in influencing its international endeavors, and (b) Firms with distinct strategic orientations pursue dissimilar combinations of overseas activities even when operating in similar country environments. These differences could be attributed to differences in strategic orientations. Besides raising concerns about the traditional economic theory of comparative costs, these findings provide several new avenues for organizational research. Building on this study many new research directions such as the performance implications of multinationality that have not been examined as yet could now be explored. / Ph. D.

The concept, sustainability, has developed throughout the years and has become an important part for different actors around the world. Due to many organizations like the United Nations acknowledging this aspect together with governments, initiatives and laws have been implemented for businesses to follow. This forms the basis of what is now called ESG which includes three individual aspects: environment, social responsibility and governance. One of the actors includes investors who have now started to shift their focus onto sustainable investments. In order for them to make decisions about the company's way of working towards a sustainable business, analytics began to measure both each individual aspect of ESG and as a whole. Therefore, ESG rating has become a well-known way of measuring how companies perform when it comes to environment, social responsibility and governance. The pharmaceutical industry in Europe is the second largest in the world and has become acknowledged due to the covid-19 pandemic. It has not only faced criticism and uncertainties both during and after the pandemic, but also faces problems in each individual aspect of ESG. When it comes to environmental issues, the pharmaceutical industry stands for 55% more of carbon emissions than the automotive sector due to non-sustainable supply chains. For the aspect, social responsibility, their main problems include addiction, antibiotic resistance and accessibility of pharmaceuticals. Further, governance issues include illegal marketing and fraud. Due to this, governments and organizations have put pressure on businesses to work towards a sustainable industry. Therefore, ESG ratings have become an important measurement for investors. The aim of the study is to analyze the relationship between ESG and financial performance in the pharmaceutical industry in Europe with a time period of 2018-2022. The results will indicate if the Shareholder’s theory or the Stakeholder’s theory is more applicable for this industry. The result shows a negative significant relationship between the overall rating of ESG and Tobin’s. When it comes to the individual aspect, governance is statically proved to have a negative significant relationship with Tobin’s Q. This concludes that the Shareholder’s theory is more aligned with the results meaning that the pharmaceutical industry may focus on profit maximization for shareholders. Since there was a non-statically proven relationship between ESG and ROA, the study suggests further research within this topic.

Thesis (MBA)--Stellenbosch University, 2002. / Some digitised pages may appear illegible due to the condition of the original hard copy. / ENGLISH ABSTRACT: A few years ago, pharmaceuticalcompanies were more inclined to look at business from the inside out. The principal focus was on the company's goals, and identifying and selling to customers were the method of achieving those goals. However,today the customer is king and therefore the focus is shifting to accommodatethis change. The road to success - or failure - is now an expressway, and companies must be ready to accelerate,tum, or stop quickly. Flexibilityand manoeuvrabilitymean a great deal in an increasinglycompetitivemarketplace(Gabe & Goldberg, 1999). What makes a sales team effective in today's competitive global market? What are the key drivers of success in pharmaceutical sales team effectiveness? The most prominent trend in the US market is customer focus, and the most prominent issue is the recruitment and retention of top performers. Today's focus on relationship building may have occurred in part because companies found that their relationships were less than ideal. Nearly 60% of US pharmaceutical companies use customersatisfaction results, among other measurements, to determine the effectiveness of their sales force. A sales force that can make the transition from selling the product to selling the solution - which is the essence of customer focus - has a better chance of earning customer confidence and "partnering" (Gabe & Goldberg, 1999). To isolate factors that make a pharmaceutical sales representative effective is not easy. The best pharmaceutical representatives have excellent selling skills and behaviours, exhibit consistent performance, build networks, contribute to their teams, focus on the most profitable accounts, open new accounts, and win customer loyalty. How does one identify top pharmaceutical salespeople? Look for the representatives with the ability to learn continuously from experience, to take full responsibility for professional development, to size up each situation, and to apply the most effective skills for that encounter. Most often, they will be the ones using consultative and adaptive selling dialogue techniques (Snader, 2002). According to the study, it was evident that the following effectiveness criteria or selling task characteristics have a definite impact on sales force effectiveness and in turn should be part of every salesperson's capabilities: territory management, objection handling, business planning, adaptive selling, customer focus, knowledge, service, selling skills and training. / AFRIKAANSE OPSOMMING: In die verlede was farmaseutiese maatskappye geneig om hul besigheid van binne na buite te ontleed. Die belangrikste fokuspunt was die maatskappy se doelwit en die identifisering van, en verkope aan hul kliënte die middel tot die doelom hierdie doelwitte te bereik. Vandag, daarenteen kraai die kliënt koning en die fokuspunt het verskuif om by hierdie verandering aan te pas. Die verskil tussen die sukses en mislukking van 'n maatskappy sal afhang van die buigsaamheid en stuurbaarheid van die maatskappy om gereed te wees vir enige aksie in hierdie toenemend mededingende mark (Gabe & Goldberg, 1999). Wat maak 'n verkoopspan doeltreffend in vandag se mededingende globale mark? Wat is die sleutel eienskappe wat sukses sal waarborg vir 'n farmaseutiese verkoopspan? Die belangrikste neiging in die Amerikaanse mark is kliënte-fokus en die mees prominente kwessie is die werwing en behoud van die top presteerders. Die fokusverskuiwing na die verhouding tussen die verkoopsverteenwoordiger en die kliënt het plaasgevind nadat maatskappye besef het hulle het nie ideale verhoudings met hulle kliënte nie. Nagenoeg 60% van alle Amerikaanse farmaseutiese maatskappye gebruik onder andere ook resultate van kliënte-tevredenheid vraelyste as 'n maatstaf om die doeltreffendheid van hulle verkoopspan te bepaal. 'n Verkoopspan wat in plaas van 'n produk verkoop eerder aan die kliënt 'n oplossing vir sy spesifieke probleem bied - wat die kern van 'n kliënt-gefokusde benadering is - skep vertroue by die kliënt en lei tot 'n suksesvolle vennootskap tussen die partye (Gabe & Goldberg, 1999). Dit is baie moeilik om eienskappe te identifiseer wat 'n farmaseutiese verteenwoordiger se doeltreffendheid verseker. Die beste farmaseutiese verkoopsverteenwoordigers gebruik uitstekende verkoopstegnieke, bou netwerke, is goeie spanlede, fokus op die mees winsgewendste kliënte, wen nuwe kliënte en die lojaliteit van hulle kliënte. Hoe word top farmaseutiese verkoopspersone dan geïdentifiseer? Kyk uit vir die verteenwoordiger wat die vermoeë het om te leer uit ondervinding, wat volle verantwoordelikheid neem vir sy persoonlike ontwikkeling, wat elke situasie ontleed en dan die toepaslike vaardighede gebruik vir die spesifieke situasie. Meestal sal dit die verteenwoordigers wees wat konsulterende en adaptiewe dialoogtegnieke gebruik (Snader, 2002). Volgens die studie was dit duidelik dat die volgende kriteria vir doeltreffende verkope of verkoopseienskappe 'n defnitiewe impak het op 'n verkoopsspan se doeltreffendheid en dus deel moet uitmaak van elke verkoopspersoon se vermoë: Areabestuur, die hantering van objeksies, besigheidsbeplanning, 'n adaptiewe verkoopstyl, 'n kliënt gefokusde benadering, kennis, diens en opleiding.

Thesis (MBA)--Stellenbosch University, 2003. / ENGLISH ABSTRACT: The purpose of this report is to create a better understanding of the new pharmacy initiatives in the South African market, with specific reference to the Nuclicks and Pick 'n Pay groups. In order to understand the respective business concepts better the following abstracts from each chapter of the study is given. Chapter one is basically the introduction to the study and describes the events that lead to the above mentioned corporate retailers to enter the pharmacy market place. An introduction to Hamel's business model theory is also discussed and identified as a possible means of evaluating the corporate retailers' business concepts. In Chapter two the strategic analysis of the South African retail pharmacy industry is performed. This analysis is performed to create an understanding of the different forces at work in the industry. Some of the key findings in this chapter are that changes to the pharmacy act and the way dispensing licences are going to be awarded creates uncertainty. The profit outlook of retail pharmacy, though on the decline, still compares favourably to other retailers. In chapter three the core concepts of Hamel's business model are presented in more detail and applied to the retail pharmacy environment. In his view, a strategy needs to change the industry rules. This chapter ends with the concept of wealth potential based on Hamel's teachings. The wealth potential concept is about creating cash flow and profits. A business model that is able to create customer benefits well below the cost of the competitors is regarded as efficient. By utilising the Hamel way the Nuclicks (chapter four) and Pick 'n Pay (chapter five) business concepts is unpacked. Both Nuclicks and Pick 'n Pay pharmacy business models are presented within the corporate framework of the groups. Nuclicks bought an established pharmacy franchise while Pick 'n Pay launched Healthpharm. Nuclicks creates a possible choke point by buying UPD. The Nuclicks pharmacy strategy is a more comprehensive health strategy, while Pick 'n Pay follows a more cautious approach. As franchising will playa major role in both pharmacy concepts, the theory of franchising is presented in chapter six. Telephonic interviews with Link franchisees are conducted and the possible reasons for the ambiguity that crept into the Link business model are discussed. As the Healthpharm franchise is a new concept, it is evaluated based on information gathered from press releases and the Healthpharm web-site. In chapter seven universal conclusions and recommendations, based upon the literature study and this investigation, are presented. One of the key findings are, success in the face of changes requires more than the current way of doing business. It requires an innovative thinking process. New business models have to be formulated that allows retail pharmacists to establish a focused and well-differentiated value proposition. This value proposition needs to be meaningful for consumers and must strengthen a pharmacy outlet's competitive position. / AFRIKAANSE OPSOMMING: Die doel van hierdie verslag is om 'n beter begrip vir die nuwe apteek inisiatiewe in die Suid-Afrikaanse mark te ontwikkel, met spesifieke verwysing na die Nuclicks en Pick 'n Pay groepe. Om die onderskeie besiqheidskonsepte beter te verstaan, word die volgende opsomming van elke hoofstuk van die studie uiteengesit. Hoofstuk een is 'n inleiding tot die studie en beskryf die gebeure wat aanleiding gegee het tot die bogenoemde korporatiewe kleinhandelaars se toetrede tot die apteek mark. 'n Inleiding van Hamel se besigheidsmodel teorie is ook bespreek en is geïdentifiseer as evaluering van die korporatiewe kleinhandelaars se besigheidskonsepte. Hoofstuk twee bied 'n strategiese analise van die Suid-Afrikaanse kleinhandelaars apteek industrie. Hierdie analise is geskep om beter begrip te ontwikkel vir die verskillende kragte wat inwerk in die industrie. Van die bevindinge in die hoofstuk is die veranderinge in die apteek wetgewing en die wyse waarop resepteer lisensies toegeken gaan word, en hoeveel onsekerhede dit tot gevolg het. Die wins vooruitsigte van kleinhandelaars apteke, alhoewel aan die afneem, vergelyk steeds gunstig met ander kleinhandelaars. In Hoofstuk drie is die kern konsepte van Hamel se besigheidsmodel in meer detail uiteengesit en toegepas op die kleinhandelaar apteek omgewing. Uit sy oogpunt, is 'n strategie nodig om veranderinge te weeg te bring in die industrie reëls. Hierdie hoofstuk eindig met die konsep van waarde potensiaal wat gebaseer is op Hamel se teorie. Hierdie waarde potensiaal konsep is gebaseer op die skep van kontantvloei en 'n Besigheidsmodel wat in staat is om die kliënt te begunstig heelwat laer as die koste van die teenstander, word beskou as effektief. Hamel se teorie is gebruik om Nuclicks (hoofstuk vier) en Pick 'n Pay (hoofstuk vyf) se besigheidskonsepte te analiseer. Beide Nuclicks en Pick 'n Pay se besigheidsmodelle word aangebied binne die korporatiewe raakwerke van die groepe. Nuclicks het 'n gevestigde apteek konsessie gekoop terwyl Pick 'n Pay vir Healthpharm begin het. Nuclicks het 'n moontlike 'wurgpunt" geskep deur die aankoop van UPD. Die Nuclicks apteek strategie is 'n meer omvattende gesondheidstrategie, terwyl Pick 'n Pay 'n meer versigtige benadering volg. Aangesien besigheid konsessie 'n belangrike rol speel in beide apteek konsepte, word die teorie van konsessie in hoofstuk ses behandel. Telefoniese onderhoude is gevoer met Link konsessiehouers en die moontlike redes vir die twyfelagtigheid van die Link besigheidsmodel word bespreek. Aangesien die Healthpharm konsessie 'n nuwe konsep is, word dit geëvalueer op grond van inligting wat versamel is uit die media en die Healthpharm webtuiste. In Hoofstuk sewe word universele afleidings en aanbevelings, gebaseer op die literatuurstudie en die ondersoek, uiteengesit. Een van die hoof bevindings was dat sukses benodig meer as die huidige manier van besigheid doen. Nuwe besigheidsmodelle moet geformuleer word, wat dit vir kleinhandelaar apteke moontlik sal maak om 'n gefokusde en goed gedifferensieerde waarde voorstel tot stand te bring. Hierdie voorstel moet betekenisvol wees vir die verbruiker en moet die apteek kompeterende posisie versterk.

藥廠在資訊科技的運用上，相較於電子業或其他高科技產業，一直都被認為是較保守的方式。究其原因，應為資訊科技在製藥業的競爭上，較難成為核心的競爭武器之一，因此，資訊科技在製藥業一直被定位為協助企業內部作業面的工具。而非協助企業達成營運目標的工具。然而，近十年來，大型跨國藥廠透過不斷地購併其他藥廠的方式，達成其擴大市場佔有率、鞏固產業中領先地位、縮短產品研發時間、及擴大產品線的廣度與深度的目的。並藉由購併後組織必須重整的過程，對組織進行人力的精減及成本的樽節。僅管跨國藥廠一直設法對人力及成本作有效的控制，但隨著購併不停地發生，不僅產品增多，組織也日益龐大，跨國藥廠所面臨到的財務、法律、人力資源、業務行銷、行政作業等各種事務也越來越繁雜。雖然跨國藥廠有其充沛的資源及豐富的跨國管理經驗，但若要能有效又即時地對全球各據點加以掌控，就必須對資訊科技的運用作全球的統一規劃，並建立全球資訊科技策略，以確實控管及協助各子公司的營運。而對各國的子公司，則應有能協助該公司在當地市場競爭的相對策略，資訊科技在市場激烈的競爭下，開始扮演越來越重要的角色。 本研究為探討性的個案研究，係以一跨國藥廠在台灣的子公司作為研究的個案，期望透過相關的文獻、對個案公司在資訊科技運用的探討、及個案公司主管對資訊科技的看法及需求，能夠達到以下的研究目的: 壹、了解跨國藥廠對資訊科技的運用現況。 貳、了解跨國藥廠發展狀況與營運方向，以規劃個案公司資訊科技的發展方向。 參、建立個案公司資訊科技策略，以提升運作績效，掌握時勢利基。 / The Pharmaceutical Industry, compared with Electronics Industry or other Hi-Tech Industries, is perceived to be relatively conservative in the application of Information Technology. The reason is being that Information Technology application to the Pharmaceutical Industry rarely plays any key role for market competition. As a consequence, Information Technology to the Pharmaceutical Industry has been an operational tool to support the back office functions, rather than a management tool to assist the business to achieve its operational goals. Nevertheless, in recent decade, giant transnational pharmaceutical companies are continuously achieving their objectives of expanding market shares, sustaining their leadership, shortening the time frame in Research and Development, and enlarging their product pipelines, through mergers and acquisitions. They have been re-deploying the human resources and implementing cost reductions by all means within the entire organization after merger and acquisition takes place and reorganization becomes necessary. Despite that transnational pharmaceutical companies have been striving to contain headcount and control expenses, they have found themselves facing to the increasingly complex operations in many aspects, including Finance, Legal, Human Resource Management, Sales and Marketing, and General Administration as a result of expansion in product pipelines and explosion in organization that comes along with mergers and acquisitions. Although transnational pharmaceutical companies have ample resources and well experienced in cross-nation management, they have to integrate their global information technology and establish a unified strategy for universal implementation, so as to enable monitoring and assisting the operations of all subsidiaries around the globe in an effective and timely manner. As such, Information Technology starts to play an increasingly important role in developing responsive strategies under the intense local market competition. This essay is a case study on a Taiwanese subsidiary owned by a transnational pharmaceutical company. It aims to achieve the following objectives by referring to relevant publications and observing the subject company’s information technology applications and their management’s views and needs on the above. 1. To understand the current applications on information technology by transnational pharmaceutical companies; 2. To understand the evolution track and business directions of transnational pharmaceutical companies to set an Information Technology development plan for the subject company. 3. To establish Information Technology Strategy for the subject company to improve operation efficiency as an advantage of obtaining timely and valuable information.

對製藥產業而言，不斷推出創新產品是其價值創造的最大動力。另一方面，市場之競爭與價格限制之壓力使所有的製藥業者莫不將提高研發的績效視為企業維持高成長的關鍵途徑。因而製藥企業一直面臨的巨大壓力便是要能快速、確實推出安全有效的新藥上市。隨著競爭模式的轉移，無形資產及知識創造之價值將是決勝的關鍵。受限於本土藥品市場規模的限制與有限的研發能量，本土製藥企業之新藥研發大多以發展階段的新藥開發為主而非風險大、時程長的新藥研究。於是瞭解智慧資本的創造、加值、運用與管理對製藥產業新產品開發績效之影響也將更為關鍵。本研究先就智慧資本之文獻與各種衡量模式進行歸納，並引用Skandia智慧資本導航者之架構，分別以人力資本、流程資本、創新資本與關係資本四個構面評量企業之創新智慧資本之內涵與建置，並試圖瞭解本土製藥產業創新智慧資本對新產品開發績效之影響，期能對我國產製藥產業智慧資本之管理方向提出建議，以提供業界進行創新智慧資本管理與發展之參考。 / The lifeblood of the pharmaceutical industry is its ability to produce innovative products. Additionally, both the heavy competition in the market and the trend of cutting price by the health insurance payers also force the industry turns their focus on increasing the performance of R&D to maintain the high growth rate. Therefore, how to launch a safe and effective new drug in a shortest time is a great challenge to the industry. Along with the changing of the core competitive advantages, the value of the intangible assets and knowledge creation become the key success factors. Linking intellectual capital management with R&D activities in pharmaceutical companies would be a critical factor in enhancing R&D performance. For a local pharmaceutical, limited by the market size and the R&D ability, the R&D activities would be more on the development phase than research phase. The relationship between intellectual capital with new product development would be more critical especially in this knowledge-base pharmaceutical industry. By literature review and adopting the intellectual capital assessment model of the Skandia Nevigator, the study divides the intellectual capital into human capital, processes capital, innovation capital and relationship capital and try to find the elements of innovative intellectual capital related to new drug development in a local pharmaceutical company. It also tries to find out how a local pharmaceutical company creates and manages its innovative intellectual capital. The research results show the current situation about intellectual capital of the case and will be provide a reference for the industry and further research.